| Ms Patricia L Briick, RPH | |
|
4001 W Algonquin Rd, Algonquin, IL 60102-9401 | |
| (224) 569-2582 | |
| Not Available |
| Full Name | Ms Patricia L Briick |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4001 W Algonquin Rd, Algonquin, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013299163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051-036680 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patricia L Briick, RPH 4001 W Algonquin Rd, Algonquin, IL 60102-9401 Ph: (224) 569-2582 | Ms Patricia L Briick, RPH 4001 W Algonquin Rd, Algonquin, IL 60102-9401 Ph: (224) 569-2582 |
News Archive
SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.
During the past decade in the United States, increasing attention has been paid to lowering the incidence of multiple gestations resulting from the use of assisted reproductive technology. To determine whether such efforts have been successful, we assessed national trends in embryo-transfer practice patterns and in outcomes after the use of assisted reproductive technology.
Today, Lung Cancer Alliance announced that its efforts to secure increased federal research funding for lung cancer achieved another victory as an additional $12.8 million was included in the Department of Defense Congressionally Directed Medical Research Program which was part of the FY2011 budget compromise approved by Congress.
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
​Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
› Verified 7 days ago
Margeurite Sue Darguzis Thomas, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 E Algonquin Rd, Algonquin, IL 60102 Phone: 847-658-4036 | |
Dr. Kenneth K Phu, PHARMA-D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 750 S Randall Rd, Algonquin, IL 60102 Phone: 847-458-5341 Fax: 847-458-5341 | |
Peter Koch, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 E Algonquin Rd, Algonquin, IL 60102 Phone: 847-658-4032 | |
Jolanta Grys, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 107 S Randall Rd, Algonquin, IL 60102 Phone: 847-854-8274 Fax: 847-854-5302 | |
Dr. Anna Ciukaj, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4001 W Algonquin Rd, Algonquin, IL 60102 Phone: 224-569-2582 | |
Mrs. Sapana Patel, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4001 W Algonquin Rd, Algonquin, IL 60102 Phone: 224-569-2582 |